Conditions: Adenocarcinoma Non-small Cell Lung Cancer
Keywords: Tarceva Erlotinib OSI-774 Adenocarcinoma Advanced Lung Cancer
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 84
Healthy volunteers: no

Brief summary:
The purpose of this trial is to figure out what effects (good or bad) the investigational drug agent called Tarceva (erlotinib; OSI-774) has on women with previously untreated adenocarcinoma.

Detailed description:
Patients will start taking Tarceva daily by mouth on Day 1 and will continue taking this medication daily at home, until participation in the study ends.

Arms:
arm 1: Erlotinib: 150 mg orally once daily without interruption Cycle duration considered 4 weeks and treatment duration indefinite until disease progression, unacceptable toxicity or withdrawal for other reasons.

Interventions: intervention 1: Erlotinib
Intervention descriptions: intervention 1: None

Protocol document: